Boehringer Ingelheim beefs up vet portfolio with GST buyout

One year after the European launch of Arti-Cell Forte — a stem cell product used to treat lameness in horses — Boehringer Ingelheim has acquired Belgian veterinary biotech company Global Stem cell Technology (GST) with an eye to expanding its portfolio of animal health drugs.